
Telotristat Ethyl (XERMELO®) – an oral treatment for Carcinoid Syndrome Diarrhea not adequately controlled by Somatostatin Analogues
Share on facebook Facebook Share on twitter Twitter Share on pinterest Pinterest Share on whatsapp WhatsApp Share on email Email 1st Aug 2020 updateIn a move that Lexicon Pharmaceuticals Inc. chief Lonnel Coats said will focus the company on its phase II neuropathic pain program, The Woodlands, Texas-based venture has agreed to sell one of its two approved products, the carcinoid syndrome diarrhea therapy Xermelo (telotristat ethyl), to Tersera Therapeutics LLCI don't expect this to make any difference to the drug or its supply. Business as usual. The outer package may change to reflect new owners but the brand name XERMELO will most likely be part of the sale. Read the news from Lex Pharma - click here. Telotristat Ethyl is a significant introduction to the treatment of Carcinoid Syndrome diarrhea. It's the…